Clinical trials: Drug Drug Interaction Study
Healthy
Drug Interaction Study of Digoxin and BI 10773
The objective of the study is to investigate the relative bioavailability of digoxin after concomitant multiple oral administration of BI 10773 and a single dose of digoxin in comparison to digoxin given alone to healthy male and…
- Trial name
- NCT01306175
- Testing
- Digoxin plus BI 10773, Digoxin
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Gout
NSAID Drug Interaction Study
This is a drug-drug interaction study in healthy volunteers to evaluate the potential pharmacokinetic (PK) effects of non-steroidal anti-inflammatory drugs on lesinurad and leinurad on the non-steroidal anti-inflammatory drugs.
- Trial name
- NCT01884272
- Testing
- lesinurad 400 mg, naproxen 250 mg, indomethacin 25 mg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Ardea Biosciences, Inc.
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Lopinavir/Ritonavir
Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole
The purpose of this two part study is to assess the effect of multiple doses of isavuconazole on the pharmacokinetics of multiple doses of lopinavir/ritonavir and the effect of multiple doses of lopinavir/ritonavir on the…
- Conditions
- Pharmacokinetics of Isavuconazole, Pharmacokinetics of Lopinavir/Ritonavir, Healthy Volunteers
- Trial name
- NCT01660477
- Testing
- Isavuconazole, Lopinavir/ritonavir
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Healthy
Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)
Fixed sequence, 2-period crossover study to compare the pharmacokinetic profiles of Palbociclib in absence and presence of prior administration of proton pump inhibitor Rabeprazole.
- Trial name
- NCT01918176
- Testing
- Palbociclib alone, Palbociclib + Rabeprazole
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypertension With Hyperlipidemia
Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers
study to evaluate drug-drug interaction following oral administration of telmisartan/amlodipine and atorvastatin in healthy adult volunteers
- Trial name
- NCT03461081
- Testing
- telmisartan/amlodipine and atorvastatin
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
Infection, Human Immunodeficiency Virus
A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)
This is an open-label, single sequence, 4-cycle, 4-treatment, drug-drug interaction (DDI) study in healthy female subjects on oral contraceptives (OC). There is no formal research hypothesis to be statistically tested.
- Trial name
- NCT02480881
- Testing
- BMS-663068, Oral Contraceptive, Loestrin 1.5/30
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
NASH - Nonalcoholic Steatohepatitis
Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers
This is a non-randomized, 2-part, open-label, drug-drug interaction (DDI) study to evaluate the effect of concomitant administration of fluconazole or quinidine on the pharmacokinetics and safety of EDP-305 in healthy human…
- Trial name
- NCT03610945
- Testing
- Fluconazole, Quinidine, EDP-305
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Healthy Male Volunteers
Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501
A Randomized, Open-label, Crossover Study to Investigate the Pharmacokinetic drug interactions and the Safety between HGP1607 and HGP1501 in Healthy Male Volunteers
- Trial name
- NCT03089112
- Testing
- HGP1607, HGP1501, HGP1607+HGP1501
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.
This is a drug-drug interaction study to compare the pharmacokinetics of a 2 mg oral dose of midazolam in adult healthy women of non-childbearing potential when administered alone and when administered along with 8 daily 125 mg…
- Trial name
- NCT01756781
- Testing
- Midazolam, PD-0332991
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers
The purpose of this study is to evaluate the drug-drug interaction between steady-state concentrations of CYP3A4 or ritonavir and TMC435350 after its first and the last dose of the multiple dosing regimen and to explore the short…
- Trial name
- NCT01891851
- Testing
- TMC435350 200 mg, Ritonavir 100 mg
- Where
- Belgium
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Healthy; Adult; Volunteer; Colchicine; Pharmacokinetics; Diltiazem; Cytochrome p450 3A4; P-glycoprotein
Drug-Drug Interaction Study Between Colchicine and Diltiazem ER
Colchicine is a substrate for both cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). Extended-release diltiazem (diltiazem ER) is a potent inhibitor of both CYP3A4 and P-gp.
- Trial name
- NCT00983372
- Testing
- Colchicine, Diltiazem ER
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mutual Pharmaceutical Company, Inc.
Dermatitis Atopic
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
This is an open-label, single group, 2-period, Phase 1, single-sequence study. The study duration will be up to 342 days. The treatment period will be up to Week 29, where Week 29 is defined as End of Treatment (last amlitelimab…
- Trial name
- NCT06686628
- Testing
- Amlitelimab, Midazolam, Caffeine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Sanofi
Healthy Subjects
Evaluation of Drug Interaction Between HS-10234 and Emtriccitabine
The study is being conducted to evaluate drug interaction between HS-10234 and Emtricitabine after multiple dose in healthy subjects.
- Trial name
- NCT04477096
- Testing
- HS-10234, Emtricitabine
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Adult, Drug Interactions
Effect of Multiple Doses of Modafinil on the Pharmacokinetics of Single Dose Lorlatinib in Healthy Participants
The primary purpose of the study is to characterize the safety profile of lorlatinib in the presence of a moderate CYP3A4/5 inducer, modafinil.
- Conditions
- Adult, Drug Interactions, Healthy Volunteers, Humans
- Trial name
- NCT03961997
- Testing
- Lorlatinib 50 mg, Lorlatinib 75 mg, Lorlatinib 100 mg
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Erectile Dysfunction
Drug Interaction Study of Avanafil and Enalapril or Amlodipine
The purpose of this study is to determine the change in the blood pressure and pulse rate, pharmacokinetics and the safety when avanafil is taken with either enalapril or amlodipine.
- Trial name
- NCT01117038
- Testing
- avanafil and enalapril, avanafil and amlodipine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)
A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body
This study will be an open-label, fixed sequence study in healthy subjects (vasectomized males and females of non-childbearing potential), performed at a single study centre.
- Trial name
- NCT04712396
- Testing
- Capivasertib, Itraconazole
- Where
- Germany
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Drug Interactions
Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects
This is a Phase 1, open-label, fixed-sequence, 2-part DDI study. Subjects will participate in only 1 study part.
- Trial name
- NCT05657613
- Testing
- CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Drug Interaction
A Study to Evaluate Drug-drug Interaction of ZX-7101A Tablets and Oseltamivir Phosphate Capsules in Healthy Adult Subjects
The primary object of this study is evaluating the effect of multiple oral oseltamivir phosphate capsules on the pharmacokinetic profile of the active metabolite ZX-7101 after a single oral administration of ZX-7101A tablet in…
- Trial name
- ZX-7101A-208 (NCT06057103)
- Testing
- ZX-7101A, Oseltamivir, ZX-7101A and Oseltamivir
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Solid Tumor, Adult
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
This is an open-label, non-randomized, clinical study to evaluate the drug interaction between itraconazole, rifampin or Cocktail and JMKX001899 in healthy subjects.
- Trial name
- NCT06348290
- Testing
- JMKX001899, Itraconazole, Midazolam
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Jemincare
Healthy
A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers
The purpose of the study is to assess the effect of multiple oral doses of canagliflozin on a single oral dose of warfarin.
- Trial name
- NCT01195324
- Testing
- Canagliflozin/Warfarin
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.